| Filed On | Filing |
|---|---|
| 27 Jan 2025 |
8-K/A: Regulation FD Disclosure
On January 27, 2025, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin participated in a Virtual Investor “What this Means” segment. |
| 13 May 2024 |
8-K/A: Results of Operations and Financial Condition
Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) |
| 23 Aug 2023 |
8-K/A: Regulation FD Disclosure
On August 21, 2023, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein. The information contained in Item 7.01... |
| 16 Jun 2023 |
8-K/A: Submission of Matters to a Vote of Security Holders
This Current Report on Form 8-K/A (this “Amended Form 8-K”) to the Current Report filed by Moleculin Biotech, Inc. (the “Company”) on May 26, 2023 (the “Original Form 8-K”) is being filed solely in order to report the final voting result... |
| 12 Apr 2022 | 8-K/A: Regulation FD Disclosure |
| 03 Feb 2021 | 8-K/A: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more |
| 04 Aug 2020 | 8-K/A: Submission of Matters to a Vote of Security Holders |
Loading...
